Scholar Rock (SRRK) Scheduled to Post Earnings on Thursday

Scholar Rock (NASDAQ:SRRK) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Scholar Rock to post earnings of ($0.61) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, May 7th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.11). During the same quarter in the prior year, the business posted ($0.46) EPS. On average, analysts expect Scholar Rock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Scholar Rock Trading Up 1.5 %

Shares of SRRK stock opened at $8.52 on Wednesday. The firm has a 50-day moving average price of $8.83 and a 200 day moving average price of $12.71. The company has a market capitalization of $679.47 million, a P/E ratio of -4.08 and a beta of 0.85. Scholar Rock has a 12-month low of $5.93 and a 12-month high of $21.17. The company has a quick ratio of 6.58, a current ratio of 6.58 and a debt-to-equity ratio of 0.24.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SRRK. BMO Capital Markets lifted their price objective on Scholar Rock from $29.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, June 13th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Scholar Rock in a research note on Tuesday, June 25th. Finally, Wedbush reaffirmed an “outperform” rating and set a $23.00 target price on shares of Scholar Rock in a report on Tuesday, May 7th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $26.00.

Insider Activity at Scholar Rock

In other news, CFO Edward H. Myles sold 9,458 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $8.98, for a total transaction of $84,932.84. Following the completion of the transaction, the chief financial officer now directly owns 201,518 shares of the company’s stock, valued at approximately $1,809,631.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, General Counsel Junlin Ho sold 4,695 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $8.98, for a total transaction of $42,161.10. Following the sale, the general counsel now owns 204,076 shares in the company, valued at approximately $1,832,602.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 9,458 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $8.98, for a total transaction of $84,932.84. Following the completion of the sale, the chief financial officer now owns 201,518 shares of the company’s stock, valued at approximately $1,809,631.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,468 shares of company stock valued at $147,883. 26.20% of the stock is owned by insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.